SGD Pharma Grows Siliconized Glass Vial Capacity


The pharmaceutical packaging company unveils a new siliconization line at its SQLM plant in France.

Siliconization treatment. Image credit: SGD Pharma

Siliconization treatment. Image credit: SGD Pharma

SGD Pharma, a pharmaceutical packaging company, launched a new siliconization offering at its state-of-the-art Saint-Quentin Lamotte (SQLM) facility in northern France. With the latest development, the company further develops its in-house services, including in the department of vial sizes.

As those in the industry know, glass vials are normally used for pharmaceutical packaging, and this treatment is ideal for various applications, including oncology. By adding a micro-layer silicone-based internal coating to the container, there is now a protective barrier that limits interaction between the drug product and the primary packaging, without compromising the quality of therapeutic products. It is applicable to all glass types, with vial sizes ranging from 3ml to 500ml in both clear and amber glass, at a high processing capacity.

In order to provide greater performance of this thin layer, SGD Pharma’s treatment uses an optimized spraying process that reportedly provides coverage of the entire vial surface. This is all done in an ISO 15378 certified facility.


SGD Pharma expands capacity of siliconized glass vials with the announcement of a new siliconization line at its Center of Excellence for Type I glass in France. SGD Pharma. January 22, 2024. Accessed January 31, 2024.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.